Commissions
Navigation Links
Commissions in Medical News
BTIG To Hold 7th Commissions for Charity Day
anticipated donationS to benefit local charities NEW YORK, May 18 /PRNewswire/ -- BTIG LLC, an institutional broker dealer specializing in trading and related brokerage services, will donate equity and derivative trading commission profits earned on Tuesday, May 19 to a group of nonprofit or...AHIP Statement on New CMS Guidelines for Agent and Broker Commissions in Medicare Advantage
WASHINGTON, Nov. 10 /PRNewswire-USNewswire/ -- Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), today issued the following statement on new guidelines announced by CMS on agent and broker compensation for Medicare Advantage plans: "We commend CMS for taking this i...SAFC Pharma Commissions HPAPI Conjugates Facility at St. Louis
ST. LOUIS, Sept. 29 /PRNewswire-FirstCall/ -- SAFC Pharma(TM), a focus area within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL ), today announced details of a new suite that has been commissioned at its St. Louis campus that will produce high-potency active pharmaceutical ingre...ATLANTA, June 3 /PRNewswire/ -- Physicians at California's San Antonio Community Hospital in Upland, will soon treat patients using the new Leksell(R) Gamma Knife Perfexion(TM). A revolutionary alternative to traditional open-brain surgery and daily radiation treatments, Leksell Gamma Knife Pe...
Chiefs Of Regional Commissions For Animal Health Announced
Dr. Robert Thwala, the Ministry of Agriculture Director of Veterinary and Livestock Services, was anointed as President of the African Regional Commission //for the International Committee of the World Organisation for Animal Health (OIE). Dr. Barry O’Neil was earlier elected the President of...MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
...fering of 3,500,000 shares of its common stock at a public offering price of $9.70 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $31.4 million. MAP Pharmaceuticals has granted the underwriters of the offering a 30-day option to purc...NHP Reports 2009 Second Quarter Results
...ation 756 777 1,570 1,524 Lease commissions and tenant and capital improvements (1,343) (1,047) ... Deferred finance cost amortization 3,120 3,120 Lease commissions and tenant and capital improvements (5,608) (5,...West Announces Second Quarter 2009 Results
... increase included additional spending on information systems, including depreciation and other project-related costs, and outside services, including commissions and acquisition-related legal services. Research spending was substantially unchanged from the prior-year quarter. Resulting operating profit was $34...Hospira Reports Second-Quarter 2009 Results
... $402.0 $338.3 Trade accounts payable 200.4 231.5 Salaries, wages and commissions 121.2 144.7 Deferred income taxes - 1.5 Other accrued liabilities ...Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants
... overallotment option. The Company received approximately $40.3 million in net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses. Each warrant has an exercise price of $1.70 per warrant share, for total potential additional gross proceeds t...Commissions in Medical Technology
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...
... and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...
Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
...on for our products or product candidates. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward......rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...
PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
... for our products or product candidates. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...... and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...
U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue relian...Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
...ly market products, and other factors which may be beyond the control of either Transition or Lilly. Please see Transition's filings with the Canadian commissions and Lilly's filings with the U.S. Securities and Exchange Commission for further information about risk factors and other cautionary statements. Neith...Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
...n Stock at a price of $0.65 per share resulting in gross proceeds of $650,000. WestPark Capital, Inc. acted as placement agent and received $65,000 in commissions and $26,000 representing a non-accountable expense fee. Lixte also issued to WestPark five year warrants to purchase up to 100,000 shares of the Compa...Commissions in Biological News
Britain's last Neanderthals were more sophisticated than we thought
...s south east England. The project now aims to prospect more widely across the region for similar sites. Barney Sloane, Head of Historic Environment commissions at English Heritage, said: "Sites such as this are extremely rare and a relatively little considered archaeological resource. Their remains sit at a k...Unmanned aircraft to study Southern California smog and its consequences
...g effects for the first time over California, and this data will likely help California reduce its global warming commitment. The California Energy commissions Public Interest Energy Research (PIER) program will employ CAPPS results in an analysis of the potential future economic and ecological consequences o...Proposal to step up cardiovascular disease research
... existing projects, and in particular the European Vascular Genomics Network (EVGN), which has been running since January 2004 as part of the European commissions FP6 framework research programme. EVGN has been promoting multidisciplinary interaction between 30 world class basic and clinical institutions in 11 E...Tiny fish can yield big clues to Delaware River health
...e new habitats for the bridle shiner. The results of the Academys studies, which will continue into 2008, will factor into the Delaware River Basin commissions flow management plans for the river. Bridle shiner prefer slow-moving, shallow waters that flow over beds of aquatic plants. The Upper Delaware River ...Commissions in Biological Technology
- Marks the first deployment of the system intended for hospitals and industrial facilities -
NORTHBROOK, Ill., and ANKLESHWAR, India, April 23 /PRNewswire/ -- PEAT
International, Inc., ("PEAT") a global leader in plasma-based waste
remediation solutions, announced toda...
... and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...
Exciton Technologies receives FDA approval to market exSALT(TM)
...sequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue relia...Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
...ounced the pricing of an underwritten offering of 7,248,936 shares of its common stock at a price of $3.14 per share. After underwriting discounts and commissions and estimated offering expenses, the company expects to receive net proceeds of approximately $21.2 million. All of the shares are being sold by Iden...... and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward...
Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
...general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
...rtainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue relian...Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
... of $7.50 per share, resulting in expected net proceeds to the company of approximately $81.6 million (after payment of the underwriting discounts and commissions and estimated expenses). Leerink Swann LLC acted as sole book-running manager for the offering. Lazard Capital Markets LLC, Canaccord Adams ...Cell Therapeutics, Inc. Announces Exercise of Overallotment
...common stock, for aggregate gross proceeds of approximately $43.9 million. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $40.3 million. Each warrant has an exercise price of $1.70 per warrant share...Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
...irstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement on Form S-3 with the United States Securities and Exchange Commission...Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
...954 additional shares of its common stock to cover overallotments, if any. The net proceeds to the Company after deducting underwriting discounts and commissions and estimated offering expenses, excluding any exercise of the underwriter's overallotment option, are expected to be approximately $35.0 million. ...Other TagskinkinkinkinkinkinkinkinexamineexaminelengthlengthOther Contentscolitiscolitiscolitisulcerativeulcerativeulcerativeulcerativeulcersulcersulcersulcersulcersulcersherniaherniaherniaumbilicusunconsciousnessunconsciousnesstesticletesticleundescended
(Date:11/8/2009)..., 3D Global Solutions is ... program managing the proposal effort for ReSound ... VA Digital Hearing Aid contract. The award includ...the Department of Defense and other federal agenci...) November 8, 2009 -- 3D Global Solutions is pleas...
(Date:11/8/2009)..., "One victory does not mean the battle is w...Nov. 7 In a vote of 240...-Lipinski-Smith Amendment to prohibit abortion man...loor. ,, Americans United for Life Action Presi...e of this amendment is a victory for the pro-life ...
(Date:11/8/2009)..., WASHINGTON, Nov. 8 /PRNewswire-USNewswire/ ...ry, Director, Operation Rescue Insurrecta Nex. ,...ountry have been fighting to keep child-killing by...,, Mr. Terry states: "This is a great first ste...- but we have a lot of fighting ahead of us. Our r...
(Date:11/7/2009)..., WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ ...ealth Insurance Plans (AHIP), released the followi...,, "Health plans strongly support comprehensive...is discussion by proposing a complete overhaul of ...r, we proposed guaranteed coverage, elimination of...
(Date:11/7/2009)..., HOUSTON, Nov. 7 Calling thi...ociation (AMA), the AMA President J. James Rohack,... physicians from all state and medical specialty s...olicy-making meeting, where health system reform w...com.com/cgi-bin/prnh/20081209/AMALOGO ) ,, "O...
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2[0] 3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract [1] Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People[0] Stupak Amendment Passes in Final House 'Health Care' Bill. A First Step to Victory, but Many Battles Ahead. We Must Rejoice With Caution.[0] AHIP Statement on House Passage of H.R. 3962[0] AMA President Kicks Off AMA Meeting Focused on Health Reform
(Date:11/6/2009)...a.Registration is now open for the Society of Inte...l Oncology (IO) Therapies" Webinar, which will pro...atheter treatment of liver tumors, kidney tumor ab...organization of physicians, scientists and allied ... health through pioneering advances in image-guide...
(Date:11/6/2009)...ing ants generally live in harmony with their arbo...ey run out of space in their trees of choice, the ... The research, published in the November issue of ...t that ants bore into live trees, and it reopens a...ants and plants. , Ants and certain species of p...
(Date:11/6/2009)...IA (November 06, 2009) The Monell Center and the ...the Beijing International Meeting on Taste and Sme...with the CAS, the meeting will be the first intern...hina. , Alan Leshner, Chief Executive Officer, A... and Executive Publisher of Science magazine, will...
Breaking Biology News(10 mins):Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Ants are friendly to some trees, but not others 2Monell Center joins with CAS to host Beijing meeting on taste and smell research 2GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 1GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 2GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 3GSA showcases groundbreaking aging research slated for Atlanta meeting 59757 4Global warming may spur increased growth in Pacific Northwest forests 10416 1Global warming may spur increased growth in Pacific Northwest forests 10416 2Global warming may spur increased growth in Pacific Northwest forests 10416 3Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 1Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 2Caltech scientists create robot surrogate for blind persons in testing visual prostheses 10414 3| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |